

## Drug Shortage – Lacrisert<sup>®</sup> (hydroxypropyl cellulose ophthalmic insert)

- The <u>drug shortage</u> of Bausch's <u>Lacrisert (hydroxypropyl cellulose ophthalmic insert)</u> is ongoing. Lacrisert has been unavailable for at least 90 days.
  - Bausch estimates supply will resume in July 2023.
- Lacrisert is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. Lacrisert is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. Lacrisert is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Product Description	NDC#
Lacrisert (hydroxypropyl cellulose ophthalmic insert)	24208-800-60

 Multiple over-the-counter and prescription artificial tear and ocular lubricant products are available for patients to use.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.